article Open AccessTop 1% cited
A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer
Cancer Cell · 2007 · Vol. 12(4) · pp. 395–402
Katrien Berns(The Netherlands Cancer Institute)Hugo M. Horlings(The Netherlands Cancer Institute)Bryan T. Hennessy(The University of Texas MD Anderson Cancer Center)Mandy Madiredjo(The Netherlands Cancer Institute)E. Marielle Hijmans(The Netherlands Cancer Institute)Karin Beelen(The Netherlands Cancer Institute)Sabine C. Linn(The Netherlands Cancer Institute)Ana M. González-Angulo(The University of Texas MD Anderson Cancer Center)Katherine Stemke‐Hale(The University of Texas MD Anderson Cancer Center)Michael Hauptmann(The Netherlands Cancer Institute)Roderick L. Beijersbergen(The Netherlands Cancer Institute)Gordon B. Mills(The University of Texas MD Anderson Cancer Center)Marc J. van de Vijver(The Netherlands Cancer Institute)René Bernards✉(The Netherlands Cancer Institute)
HER2/EGFR in Cancer ResearchPI3K/AKT/mTOR signaling in cancerMonoclonal and Polyclonal Antibodies ResearchPTENTrastuzumabBreast cancerPI3K/AKT/mTOR pathwayCancer researchBiomarkerMedicineCancerOncologyInternal medicine
MeSH terms
TrastuzumabAdultAgedAntibodies, MonoclonalAntineoplastic AgentsBreast NeoplasmsFemaleHumansMiddle AgedMutationTransduction, GeneticBiomarkers, TumorCohort StudiesSignal TransductionGene Expression Regulation, Neoplastic
Funding
- National Institutes of Health
Citations
1,609
FWCI
42.93
field-weighted impact
References
22
Percentile
100%
vs. same field & year
Citations per year
Cited by
The Identification of 2-(1<i>H</i>-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-<i>d</i>]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer
Journal of Medicinal Chemistry · 2008 · 741 citations
Drug Resistance in Cancer: An Overview
Cancers · 2014 · 2,424 citations
ErbB receptors and signaling pathways in cancer
Current Opinion in Cell Biology · 2009 · 975 citations
Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer
Frontiers in Oncology · 2012 · 604 citations
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Nature reviews. Cancer · 2009 · 2,438 citations
Targeting the phosphoinositide 3-kinase pathway in cancer
Nature Reviews Drug Discovery · 2009 · 2,742 citations
PTEN: Multiple Functions in Human Malignant Tumors
Frontiers in Oncology · 2015 · 458 citations
Cancer drug resistance: an evolving paradigm
Nature reviews. Cancer · 2013 · 4,512 citations
References
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Cancer Cell · 2004 · 1,856 citations
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
Journal of Clinical Oncology · 2002 · 2,949 citations
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Nature Medicine · 2000 · 2,723 citations
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
Journal of Clinical Oncology · 1999 · 2,788 citations
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
New England Journal of Medicine · 2001 · 11,439 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.